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Objective: The use of sirolimus eluting stent (SES) has strongly limited the incidence of in-stent restenosis that still
remains a problem at the stent edge. The aim of this study was to analyze the neointimal thickening after implantation of
SES and to assess the influence of the stent implantation procedure on the neointimal thickening in the in-stent segment
and at the edge of the stent in an ex-vivo model of stented human artery.
Methods: Both balloon expandable SES and the corresponding bare metal stent (BMS) were used in a model of human
mammary artery culture. Stents were implanted either directly or after predilatation (10 atm, 60 seconds) and analysis of
arterial segments were performed at 28 days poststenting. Cell proliferation and neointimal thickening were assessed by
immunohistochemistry, western blotting, and histomorphometry, both in the in-stent segment and at the edge of the
stent. Neointimal thickening was expressed as the ratio ([neointimal area/neointimal area  media area]).
Results: The in-stent neointimal thickening was dramatically inhibited in the SES group compared with the BMS group
whatever the stenting technique was (predilatation: 0.22  0.05 vs 0.30  0.10; P < .04; direct stenting 0.16  0.04 vs
0.30  0.13; P <.01). This effect of SES was associated with a smallest expression of the small G protein RhoA and an
increase of p27kip expression. In the BMS group, predilatation and direct stenting gave similar in-stent neointimal
thickening. In contrast, in the SES group, in-stent neointimal thickening was significantly reduced when direct stenting
was performed (0.16  0.04 [direct stenting] vs 0.22  0.05 [predilatation], P < .03). At the stent edge, a similar
neointimal thickening was observed with both type of stent when predilatation was performed on the entire segment of
the artery. Direct stenting significantly reduced the neointimal thickness at the stent edge when SES where used (0.06
0.01 [direct stenting] vs 0.19  0.06 [predilatation]; P < .001) but not in the BMS group.
Conclusion: These results confirm the efficiency of sirolimus released form SES to inhibit RhoA expression and to increase
p27kip level in the arterial wall and show the benefit of direct stenting to limit the edge effect with SES. (J Vasc Surg
2007;46:354-9.)
Clinical Relevance: Although SES or other drug-eluting stents (DES) reduce the need for repeated revascularization
compared with BMS, these benefits are accompanied by a delay in the normal healing process of the arterial wall to injury.
Besides the risk of thrombosis resulting from this delayed healing, edge stenosis has also been raised as a potential
limitation for DES. However, the standard SES implantation technique typically follows balloon predilatation,
particularly in clinical trials. In this study, we addressed whether the implantation technique, generally chosen at the
discretion of the interventional cardiologist, affected the consequences of SES implantation. We showed that direct
stenting significantly reduced the neointimal thickness at the SES edge. This result thus suggests that in clinical practice,
direct stenting or predilatation with balloon smaller in length that the stent could be preferentially used to limit the SES
edge restenosis.Angiographic restenosis occurs in 20% to 40% of
cases by the sixth month after coronary stenting.1 Results
of recent clinical trials show that local delivery of antim-
itotic drugs such as paclitaxel or sirolimus from drug-
eluting stents (DES) is an efficient way to prevent reste-
nosis.2-5 In these clinical trials, the standard DES
implantation technique typically follows balloon predilata-
tion. The Randomized Study with the Sirolimus-eluting
Velocity Balloon-expandable Stent (RAVEL) study has been
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354designed to compare the performance of a coronary stent that
slowly releases sirolimus with that of a standard uncoated bare
metal stent (BMS) for revascularization of single, primary
lesions in native coronary arteries. At 6 months, the degree
of neointimal proliferation was significantly lower in the
SES group than in the BMS group and none of the
patients in the sirolimus-stent group (compared with
26.6% of those in the BMS group) had restenosis.3 On
the other hand, the Sirolimus-eluting Stent in De Novo
Native Coronary Lesion (SIRIUS) study was a random-
ized, double-blind trial comparing a SES with a standard
BMS in patients who had a newly diagnosed lesion in a
native coronary artery.4 The coronary disease in the pa-
tients enrolled in the SIRIUS trial was complex because of
the frequent presence of diabetes, the high percentage of
patients with long lesions, complex lesionmorphology, and
small vessels. In this trial, the frequency of restenosis in the
SES group was 8.9%.4 Even if the two studies present some
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ent results. In fact, of 31 SES restenoses in the SIRIUS trial,
27 were focal and 19 of these focal restenoses were at the
stent edges.6
We hypothesized that lesions at the adjacent vessel
segments that might have been injured by predilatation,
stent deployment, or postdilatation and that have not been
covered by the SES could account for treatment failure at
the edge of the stent.7 In our experimental model of
in-stent restenosis in human mammary arteries, we have
previously shown that endothelial injury is significantly
reduced when the balloon expanded stent was implanted
without prior balloon dilatation.8 The aim of this study was
therefore to address this hypothesis by assessing the influ-
ence of the stent implantation procedure on the neointimal
thickening in the in-stent segment and at the edge of the
stent.
METHODS
Mammary artery samples. All the procedures have
been performed in accordance with institutional guidelines.
Stenting and organ culture were performed as previously
described.8 Briefly, unused segments of internal mammary
arteries (2 to 3 cm long) were obtained from 22 patients
undergoing coronary bypass surgery. Premedication, anes-
thesia, and intraoperative heparinization were all con-
ducted according to the usual protocol applied in our
surgery department. After withdrawal, artery segments
were immediately immersed in physiological saline solution
(composition [in mM]: 140 NaCl, 5.6 KCl, 1 MgCl2, 2
CaCl2, 11 glucose, 8 hepes, PH 7.4) and then transferred
on ice to the laboratory.
Stenting and organ culture. After microscopic dis-
section, each artery sample was separated in two parts: one
part was used for direct stenting and, in the other part, the
stent was implanted following predilatation. The BMS used
was BX Velocity™ (18 mm length, 2.5 mm in diameter;
Johnson and Johnson Co, New Brunswick, New Jersey)
and the SES used was Cypher (18 mm length, 2.5 mm in
diameter; Johnson and Johnson Co). In the predilatation
protocol, a first balloon inflation (10 atm; Medflator 2 MX
380) was applied for 60 seconds to the entire length of the
artery sample, and the balloon was removed. The stent,
mounted over a balloon of same length (18 mm), was then
implanted using an inflation pressure of 10 atm pressure for
10 seconds. In the direct stenting protocol, the stent was
directly implanted using an inflation pressure of 10 atm
pressure for 10 seconds. The stent was then implanted up
to the middle of the sample, allowing the definition of
“in-stent” segment of approximately 7 mm in length and a
non-stented region corresponding to the 7 mm region
distal to the end of the stent. All samples were then cultured
in six-well plates, immersed in a culture medium obtained
by mixing in equal part culture medium for smooth muscle
cell (Promocell, Heidelberg, Germany) and culture me-
dium for endothelial cell (Promocell), and maintained at
37°C under a 5% CO2 humidified atmosphere. The me-
dium was changed every 2 days.Histomorphometry. After 28 days of culture, sam-
ples were rinsed in phosphate-buffered saline (PBS), fixed
in formalin (3%) at 4°C for 12 hours, dehydrated in graded
ethanol series (70° to 100°C) at 4°C and acetone for 24
hours, then embedded in glycomethylmetacrylate. For
each sample, 50 m-thick sections were cut (Isomet,
Buehler France, Dardilly, France) and stained with Ver-
hoeff-van Gieson for analysis. Knowing the thickness of
each section made it easy to determine the position of the
analyzed area both for the in-stent and the edge segment.
Two zones have thus been defined in each sample: the
stent-edge, corresponding to the first 3 mm adjacent to the
stent (from the first section without strut at the distal end of
the stent), and the in-stent segment, corresponding to the
middle of the stented part of the artery. Histological sec-
tions were observed (Nikon E-600, Nikon, Champigny-sur-
Marne, France), digitized, and morphometry measurements
were performed with an image analyzer (Metamorph, Mo-
lecular Device, Downingtown, Pa) in at least three in-stent
and edge segments in each group (SES predilatation, SES
direct stenting, BMS predilatation, BMS direct stenting).
Neointimal area was measured as the area from the internal
elastic lamina to the luminal border, and media area as the
area between the internal elastic lamina and the external
elastic lamina. Neointimal thickening was expressed as the
ratio ([neointimal area/neointimal area  media area]).
Immunochemical analysis. Immunochemical analy-
sis was performed after 14 days of culture. At the end of the
desiccation process, stents were removed and arteries were
embedded in paraffin blocks that were cut into 4 m-thick
sections and then immersed in a 3% hydrogen peroxide
aqueous solution (Sigma, Lyon, France) to inhibit endog-
enous peroxidase activity. Nonspecific staining was blocked
by 10-minute incubation in 5% bovine albumin PBS. After
two washes in PBS, sections were incubated in MIB1
antibody (diluted in 1% bovine albumin PBS; Immuno-
tech, Marseille, France) to detect Ki-67 nuclear antigen,
which is associated with cell proliferation. Immunohisto-
chemical detection was performed using a labeled strepta-
vidin-biotin method (LSAB universal kit, Dako, Trappes,
France). Positive staining was revealed with diaminobenzi-
dine, and sections were then counterstained with Mayer
hematoxylin solution (Sigma, France) before observation
under light microscopy. Two independent observers
countedMIB1 stained cells in neointima andmedia areas of
sections from stent-edge and in-stent segments. Sections of
colonic adenocarcinoma known to be positive for MIB1
served as positive control. In negative control, the primary
antibody was omitted from the incubation solution.
Western blot analysis. At the end of the culture,
stented segments of arteries were homogenized in lysis
buffer, as previously described.9 After determination of
protein concentration in lysates frommammary artery sam-
ples, equal amounts of protein were loaded in each lane of
12% polyacrylamide/SDS gels, which were then electro-
phoresed and transferred to nitrocellulose. Lysates were
analyzed byWestern blot with mouse monoclonal antibod-
ies against RhoA (Santa Cruz Biotechnology, Inc, Heidel-
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(Sigma). Immunoreactive bands were visualized using
horseradish peroxidase conjugated secondary antibody and
subsequent chemiluminescence detection (Amersham
Pharmacia Biotech, Les Ulis, France).
Scanning electron microscopy. For this purpose,
samples were fixed with 4% glutaraldehyde, 0.1M phos-
phate buffer, PH 7.2 for 1 h at 4°C, and washed in PBS for
1 hour. Next they were dehydrated through a graded
ethanol and pure acetone, and critical-point dried from
CO2 (CPD 010 Bal-Tec AG, Balzers, Liechtenstein). Spec-
imens were sputter-coated with Au/Pd (Emscope, Ash-
ford, UK) for scanning electron microscopy (JSM 6300
Jeol, Tokyo, Japan) observation with secondary electrons.
Statistical analysis. All analyses were done at least in
triplicate, and results are expressed as the mean  SD. An
ANOVA test was performed on these values (P .05 being
considered as significant).
RESULTS
Effect of SES on RhoA and p27kip1 expression.
We have previously shown that addition of rapamycin (1 to
10 nM) in the culture medium induced increased in
p27kip1 expression and loss of RhoA expression in stented
Fig 1. Effect of implantation of BMS and SES stent on RhoA and
p27kip1 expression. Typical western blots and corresponding den-
sitometric analyses of RhoA and p27kip1 expression in control
arteries and in arteries stented with BMS or SES after a 28-day
culture. BMS implantation did not modify RhoA expression (left)
but induced a decrease in p27kip1 expression (right). In contrast,
SES implantation induced a loss of RhoA expression associated
with an increase in p27kip1 expression. Results were normalized to
-actin and expressed relative to that of day 0 as 1; *P .001 BMS
vs SES). Data shown are the mean of three to four independent
experiments.artery, and that this latter contributed to the antirestenoticaction of rapamycin.10 We therefore compared RhoA and
p27kip1 expression in human mammary artery implanted
with BMS or SES and cultured for 28 days. Fig 1 shows a
decrease in p27kip1 expression and no change in RhoA
level in arteries stented with BMS. In contrast, expression
of RhoA was almost completely lost in arteries stented with
the SES. This was associated with a 2.5-fold increase in
p27kip1 expression (Fig 1).
Neointimal thickening in the “in-stent segment”.
After 28 days of culture, histomorphometric analysis re-
vealed that the in-stent neointimal thickening was dramat-
ically inhibited in the SES group compared with the BMS
group whatever the stenting technique was (predilatation:
0.22  0.05 vs 0.30  0.10; P  .04; direct stenting
0.16  0.04 vs 0.30  0.13; P  .01) (Fig 2, A and B). In
the BMS group, predilatation and direct stenting gave
similar in-stent neointimal thickening (0.30  0.10 vs
0.30  0.13; NS) (Fig 2, B). In contrast, in the SES group
a smaller neointimal thickening was observed when direct
stenting was performed (0.16  0.04 [direct stenting] vs
0.22  0.05 [predilatation], P  .03).
Analysis of cell proliferation gave similar results. The
number of mitotic smooth muscle cells (MIB1 immuno-
staining) in the in-stent segment was significantly lower at
day 14 in the SES group than in the BMS group (4.62 
0.65 vs 7.57  0.98, P  .02).
Neointimal thickening in the “edge segment”. If a
predilatation is performed with a balloon longer than the
stent that will be subsequently implanted, a part of the
arterial segment damaged by the ballooning remains un-
covered by the stent. The neointimal thickening has been
analyzed in this damaged segment. Neointimal thickening
was observed in the 3 mm adjacent to the edge of the stent.
When a predilatation was performed, a similar neointimal
thickening was observed whatever the stent used (BMS:
0.16  0.06; SES: 0.19  0.06; NS) In the BMS group,
neointimal thickening was similar with both techniques of
implantation (0.16  0.06 [predilatation] vs 0.12  0.05
[direct stenting]; NS) (Fig 2, A and B). In the SES group,
direct stenting significantly reduced this neointimal thicken-
ing compared to predilatation (0.06 0.01 [direct stenting]
vs 0.19  0.06 [predilatation]; P  .001) (Fig 2, B). After
predilatation, the neointimal thickening at the edge of the
SES became similar to that measured in arteries receiving
the BMS (0.19  0.06 vs 0.16  0.06; NS).
Scanning electron microscopy. Scanning electron
microscopy demonstrated cell colonization of both BMS
and SES (Fig 3). However, the thickness of the cell layer
recovering the stents seemed to be reduced in artery im-
planted with the SES. Nevertheless, in this model, after 28
days, the SES is almost completely covered by a cell layer.
DISCUSSION
Our results demonstrate that direct stenting with SES
significantly limits neointimal thickening at the edge of the
stent (“edge effect”) in a model of human mammary arter-
ies culture at 28 days of follow-up. If a predilatation is
performed, incomplete lesion coverage by the SES may
P  .
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obtained with a BMS.
We recently showed that endothelial injury is signifi-
cantly reduced when the stent is implanted without balloon
predilatation,8 which ablates the vessel endothelium lining
as previously observed.11 Direct stenting allows preserva-
tion of endothelial cells between the struts of the stent. The
inhibitory effect of the endothelium on vascular smooth
muscle cell proliferation has been recognized for a long
time and the large number of in vitro or in vivo studies
addressing the antiproliferative action of endothelium and
endothelium-derived factors has led to extensive biblio-
graphic data. The reduced endothelial damage resulting
from direct stenting was thus expected to have a limiting
effect on vascular smooth muscle cell proliferation. In fact,
we show that the beneficial effect of direct stenting to limit
neointimal thickening was only obtained for SES but not
for BMS, and was major at the edge of the stent. Direct
stenting with a balloon identical to the stent in length
limited endothelial damage in the segment covered by the
stent and prevented endothelial denudation at stent edge.
When predilatation extending outside the zone to be
Fig 2. Neointimal thickening in stented arteries. A, Rep
arteries implanted with BMS (left) or SES (right) either
indicated the lumen, S the strut of the stent, and the aster
thickening at the edge and inside the stent. BMS (left) a
(black columns) or by direct stenting (empty columns) (*stented was performed, the neointimal thickening observedat the edge of the SES was similar to that obtained with a
BMS. This phenomenon was due to the intimal hyperplasia
and was completely prevented by direct stenting. Our
results thus suggest that elution of sirolimus from the stent
to smooth muscle cells within the arterial wall inhibited
neointimal thickening inside the stent but not outside the
stent. This was probably due to the limited longitudinal
diffusion of the molecule. Therefore, when predilatation-
induced endothelial damage in an arterial segment was not
covered by the drug-eluting stent, neointimal proliferation
occurred in this zone.
Our results thus support recent clinical data showing
the benefit of using a direct stenting strategy for coronary
DES implantation. A randomized clinical trial designed to
compare direct stenting with balloon predilatation fol-
lowed by stent placement using only DES in 166 coronary
lesions demonstrates that direct stenting resulted in a sig-
nificantly lower rate of target lesion revascularization over
12-month follow-up period compared with balloon predi-
latation followed by stenting.12 More precisely, by volu-
metric and cross-sectional intravascular ultrasound analyses
in 115 patients, the Direct Stenting using the Sirolimus-
tative sections located in the edge or in-stent segment of
predilatation or direct stenting after a 28-day culture. L
e neointimal thickening. B, Quantification of neointimal
S (right) have been implanted either after predilatation
03 and **P  .001).resen
after
isk th
nd SEeluting Stent (DIRECT) trial shows that neointimal hyper-
oth B
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(0.22 vs 0.098 mm3/mm, P  .01) when the direct
stenting strategy was used for SES compared with conven-
tional stenting using predilatation.13
In the SIRIUS trial, lesions were treated with standard
interventional techniques including mandated balloon di-
latation before stent placement, while in the E-SIRIUS
study, 26% of the lesions were treated by direct stenting.
However, in-stent restenosis was similar in both trial (3.2%
in SIRIUS vs 3.9% in E-SIRIUS).4,14 Several explanation
could account for this similarity: (1) Directly implanted
stents corresponded only to 26% of the considered stents;
(2) The clinical risk profile for restenosis was higher for
patients enrolled in E-SIRIUS (more smokers, more pa-
tients with previous myocardial infarction); and (3) The
mean reference vessel diameter was smaller, the average
lesion length was longer and the rate of multiple stent
implantation was higher in E-SIRIUS than in SIRIUS.
Therefore, even a lower rate of restenosis should be ex-
pected with direct stenting, it could not be evidenced in
these studies.
In the SIRIUS study, the frequency of in-stent reste-
nosis with SES was 3.2% while the frequency of in-segment
restenosis (that included the 5 mm segments proximal and
distal to the stent edge) was 8.9%.4 The higher rate of
Fig 3. Scanning electron microscopy of longitudinally c
microscopy demonstrated endothelial cell coverage of bin-segment restenosis was essentially due to a higher rate ofrestenosis at themargins of the stents. The exposedmargins
of stents that did not cover the entire region of the balloon
injury were the primary sites of restenosis, which occurred
predominantly at the proximal stent margin. This is in
agreement with the observation that restenosis at the SES
border was associated with incomplete endothelial lesion
coverage as detected by intravascular ultrasound15 and is
now confirm the results from the Direct Stenting using the
Sirolimus-eluting stent (DIRECT) trial.13
Taken together, these recent clinical data12,13 are thus
in agreement with our results suggesting that direct stent-
ing, or predilatation with a balloon smaller in length or in
diameter than the stent, should be preferentially used to
limit the endothelial lesion thus allowing complete cover-
ing of this lesion by SES, and matching the injured and the
biologically treated segment.
Experiments described in this study have been per-
formed ex-vivo in organ cultures using human arteries from
atherosclerotic patients. Humanmammary arteries are usu-
ally described as resistant to atherosclerosis. Nevertheless,
atherosclerotic lesions have been described in 12% of hu-
man mammary arteries from patients with coronary artery
disease.16 In agreement with this study, we have regularly
observed zones of intimal thickening without atheroscle-
rotic plaques in our mammary artery samples. Hodgson
nted arteries after 28 days of culture. Scanning electron
MS (A) and SES (B).ut steand Marshall17 have reported endothelial dysfunction in
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endothelial dysfunction may occur in the absence of angio-
graphically or ultrasonographically revealed atherosclerosis
in patients with risk factors for atherosclerosis.18 This dys-
function can be observed a long time before histologic
lesions become apparent. Thus, it may be assumed that the
human mammary arteries used in our study displayed en-
dothelial dysfunction similar to that of atherosclerotic cor-
onary arteries undergoing stent implantation.
Influence of factors depending of blood flow, including
recruitment of immune/inflammatory cells that may par-
ticipate for these processes in vivo is not present in this
model. However, our results indicate that neointimal for-
mation comprises an intrinsic component, resulting from
the vessel wall response to stent insertion. The characteris-
tics of the neointimal thickening obtained in organ culture
and the observed inhibitory effect of rapamycin suggest
that the neointimal formation process in organ culture
resembles that occurred in vivo, in which blood factors
could play amplifying but not necessary role.
The present results obtained in ex-vivo stented human
mammary indicate that sirolimus diffuses from the SES to the
arterial wall and acts on arterial smooth muscle cells to reduce
in-stent neointimal thickening. The decreased in-stent neoin-
timal thickening observed with the SES was associated with a
reduced expression of the small G protein RhoA and an
increase of p27Kip1 expression in smooth muscle cells, which
are both typical effects of rapamycin.10,19 Electron scanning
microscopy revealed however that these effects did not
prevent cell coverage of the stent. Neointimal thickening
was observed at the edge of the SES when the implantation
was preceded by predilatation extending outside the
stented zone. This phenomenon was completely prevented
by direct stenting. These results, together with recent clin-
ical trials12,13 thus suggest that in clinical practice, direct
stenting or predilatation with balloon smaller in length that
the stent, should be preferentially used to limit the SES
edge restenosis.
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